10 Best Nephrogen Alternatives & Competitors (2026)

Editas Medicine focuses on CRISPR gene editing for ocular and hematologic diseases using AAV vectors with established tropism. While it has clinical experience and intellectual property around editing technologies, its delivery vehicles are not engineered for the kidney or pancreas efficiency gains Nephrogen claims with NeFIND.

Intellia Therapeutics advances in vivo CRISPR therapies using lipid nanoparticle delivery mainly targeting the liver. Its approach avoids AAV immunogenicity issues but lacks the tissue-specific AAV engineering Nephrogen pursues for kidney and pancreatic indications.

REGENXBIO develops and licenses AAV vectors for retinal, neurological, and metabolic diseases. It offers a portfolio of capsids with broad or liver-biased tropism, differing from Nephrogen's AI-optimized kidney and pancreas-specific vehicles in both target tissue and discovery method.

Beam Therapeutics applies base editing with AAV and lipid nanoparticle delivery for genetic diseases, primarily liver and blood disorders. Its editing precision is a strength, but like most peers it lacks Nephrogen's specialized focus on renal and pancreatic tropism.

Sarepta Therapeutics specializes in RNA-based and gene therapies for neuromuscular diseases using AAV vectors. Its programs emphasize muscle delivery and have reached late-stage trials, yet it does not target the kidney or pancreas delivery challenges central to Nephrogen's mission.

Voyager Therapeutics engineers AAV capsids for CNS delivery using directed evolution. Its technology improves brain targeting but does not address the kidney or pancreas efficiency and immunogenicity improvements demonstrated by Nephrogen's NeFIND platform.

Spark Therapeutics, now part of Roche, commercializes AAV gene therapies for ocular and liver diseases. It has approved products and established manufacturing, yet its vectors are not optimized for the kidney and pancreas indications Nephrogen prioritizes.

Bluebird Bio develops ex vivo gene therapies for blood disorders using lentiviral vectors. Its approach bypasses in vivo delivery challenges but does not compete directly with Nephrogen's in vivo AAV platform for solid organ targeting.

Vertex Pharmaceuticals invests in gene editing partnerships for rare diseases, largely leveraging existing delivery systems. Its scale and clinical expertise exceed Nephrogen's current stage, but it has not published kidney- or pancreas-specific AAV innovations comparable to NeFIND.